- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Akebia Ther (AKBA)
Akebia Ther stock price live, this page displays NASDAQ AKBA stock exchange data. View the AKBA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Akebia Ther real time stock price chart below.
What Is the Akebia Ther Stock Price Today?
The Akebia Ther stock price today is 0.980.
What Is the Stock Symbol for Akebia Ther?
The stock symbol for Akebia Ther is "AKBA."
What Stock Exchange Does Akebia Ther Trade On?
Akebia Ther is listed and trades on the NASDAQ stock exchange.
Is Akebia Ther a Good Stock to Buy?
Determining whether Akebia Ther—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKBA quote. (ISIN: US00972D1054)
What Is the Akebia Ther Stock Price Today?
The Akebia Ther stock price today is 0.980.
What Is the Stock Symbol for Akebia Ther?
The stock symbol for Akebia Ther is "AKBA."
What Stock Exchange Does Akebia Ther Trade On?
Akebia Ther is listed and trades on the NASDAQ stock exchange.
Is Akebia Ther a Good Stock to Buy?
Determining whether Akebia Ther—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKBA quote. (ISIN: US00972D1054)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.940
1.000
52 wk Range
0.814
3.200
AKBA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9401.000
52 wk Range
0.8143.200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AKBA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
3.917
Upside
+299.66%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Akebia Ther receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Akebia Ther receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Akebia Ther receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.917
(+299.66% Upside)
Akebia Ther Earnings Call Summary for Q2/2026
- Akebia posted Q2 2026 adjusted loss of $0.03/share, beating estimates by $0.01, but revenue fell 21.5% YoY to $49M, missing forecasts by $1.93M.
- Vafseo sales surged 60% YoY to $21.3M with 10,500+ active patients, while Auryxia plunged 46% to $25.5M amid generic competition and pricing pressure.
- Shares dropped 24% after-hours to $0.98 as management warned 2027 revenue could decline when Vafseo's TDAPA premium pricing ends December 31, 2026.
- VOICE trial met primary endpoint, strengthening Vafseo's clinical profile; Phase II trials progressing for ebribafusp and praliciguat in rare kidney diseases.
- Company holds $155.5M cash, expects two-year runway with planned debt refinancing; DaVita adoption remains gradual despite operational progress discussions.
Last Updated: 2026-08-05, 05:26 p/m
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
-0.03 / -0.04
Revenue / Forecast
49M / 50.93M
Compare AKBA to Peers and Sector
Metrics to compare | AKBA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAKBAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.2x | −2.6x | −0.4x | |
PEG Ratio | −0.30 | −0.02 | 0.00 | |
Price/Book | 10.9x | 1.4x | 2.6x | |
Price / LTM Sales | 1.2x | 2.1x | 3.1x | |
Upside (Analyst Target) | 299.7% | 133.0% | 52.9% | |
Fair Value Upside | Unlock | 6.9% | 6.4% | Unlock |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Akebia Ther (AKBA) Stock Price Today?
The Akebia Ther stock price today is 0.980 USD.
What Stock Exchange Does Akebia Ther Trade On?
Akebia Ther is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Akebia Ther?
The stock symbol for Akebia Ther is "AKBA."
What Is the Akebia Ther Market Cap?
As of today, Akebia Ther market cap is 271.560M USD.
What Is Akebia Ther's Earnings Per Share (TTM)?
The Akebia Ther EPS (TTM) is -0.111.
When Is the Next Akebia Ther Earnings Date?
Akebia Ther will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is AKBA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Akebia Ther Stock Split?
Akebia Ther has split 0 times.
How Many Employees Does Akebia Ther Have?
Akebia Ther has 194 employees.
What is the current trading status of Akebia Ther (AKBA)?
As of Sep 23, 2026, Akebia Ther (AKBA) is trading at a price of 0.980 USD, with a previous close of 0.980 USD. The stock has fluctuated within a day range of 0.940 USD to 1.000 USD, while its 52-week range spans from 0.814 USD to 3.200 USD.
What Is Akebia Ther (AKBA) Price Target According to Analysts?
The average 12-month price target for Akebia Ther is 3.917 USD, with a high estimate of 6 USD and a low estimate of 1 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +299.66% Upside potential.
What Is the AKBA Premarket Price?
AKBA's last pre-market stock price is 0.978 USD. The pre-market share volume is 3,350.000, and the stock has decreased by -0.002, or -0.200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.